Suppr超能文献

11β-羟类固醇脱氢酶1型活性可预测糖皮质激素对骨骼的影响。

11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone.

作者信息

Cooper Mark S, Blumsohn Aubrey, Goddard Philippa E, Bartlett William A, Shackleton Cedric H, Eastell Richard, Hewison Martin, Stewart Paul M

机构信息

Division of Medical Sciences, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, United Kingdom.

出版信息

J Clin Endocrinol Metab. 2003 Aug;88(8):3874-7. doi: 10.1210/jc.2003-022025.

Abstract

Individual susceptibility to glucocorticoid-induced osteoporosis is difficult to predict clinically. We recently characterized expression of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in human osteoblasts. This enzyme generates active cortisol (or prednisolone) from inactive cortisone (or prednisone) and regulates glucocorticoid action in vitro. We, thus, hypothesized that osteoblastic 11beta-HSD1 mediates susceptibility to glucocorticoid-induced osteoporosis. Twenty healthy males ingested 5 mg prednisolone twice daily for 7 d, and relationships between changes in bone turnover markers and urinary measures of corticosteroid metabolism were examined. The bone formation markers osteocalcin and N-terminal propeptide of type I collagen decreased in all subjects (P < 0.001), but resorption markers were unchanged. The extent of fall in formation markers correlated with baseline 11beta-HSD1 activity with high activity predicting the greatest fall [for osteocalcin d 4 and 7, r = -0.58 and -0.56 (P < 0.01); for N-terminal propeptide of type I collagen d 4, r = -0.51 (P < 0.05)]. There was no correlation with measures of glucocorticoid inactivation or total corticosteroid metabolite production. Urinary measures of 11beta-HSD1 activity predict the response of bone formation markers to glucocorticoids, and this appears to reflect increased generation of active glucocorticoids within osteoblasts. Measures of 11beta-HSD1 activity may predict individual susceptibility to glucocorticoid-induced osteoporosis, and these data should facilitate the development of bone-sparing glucocorticoids.

摘要

临床上很难预测个体对糖皮质激素诱导的骨质疏松症的易感性。我们最近对人成骨细胞中11β-羟基类固醇脱氢酶1型(11β-HSD1)的表达进行了表征。该酶可将无活性的可的松(或泼尼松)转化为活性皮质醇(或泼尼松龙),并在体外调节糖皮质激素的作用。因此,我们推测成骨细胞中的11β-HSD1介导了对糖皮质激素诱导的骨质疏松症的易感性。20名健康男性每天两次摄入5mg泼尼松龙,持续7天,并检测骨转换标志物变化与皮质类固醇代谢尿液指标之间的关系。所有受试者的骨形成标志物骨钙素和I型胶原N端前肽均下降(P<0.001),但骨吸收标志物未改变。形成标志物下降的程度与基线11β-HSD1活性相关,高活性预示着最大程度的下降[骨钙素第4天和第7天,r=-0.58和-0.56(P<0.01);I型胶原N端前肽第4天,r=-0.51(P<0.05)]。与糖皮质激素失活或总皮质类固醇代谢产物生成指标无关。11β-HSD1活性的尿液指标可预测骨形成标志物对糖皮质激素的反应,这似乎反映了成骨细胞内活性糖皮质激素生成增加。11β-HSD1活性指标可能预测个体对糖皮质激素诱导的骨质疏松症的易感性,这些数据应有助于开发保骨的糖皮质激素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验